Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Subscribe To Our Newsletter & Stay Updated